最新消息
獲取40%折扣優惠 0
🔑 精選股票觀點,五一輕鬆解鎖財富密碼 領取限時優惠
關閉

AXA Framlington Biotech Fund - R Accumulation(0P0000XMRD)

建立提醒
新的!
建立提醒
網站
  • 作為提醒通知
  • 您要登陸到您的賬戶才能使用此功能
移動應用程序
  • 您要登陸到您的賬戶才能使用此功能
  • 請確保您使用相同的用戶資料登入

條件

頻率

一次
%

頻率

頻率

傳達方式

狀態

從投資組合中新增/移除 新增至觀察名單
加入觀察名單
新增持倉盤

頭寸被成功添加到:

請為您的持倉投資組合命名
 
5.135 +0.090    +1.74%
02/05 - 關閉. GBP 貨幣 ( 免責聲明 )
種類:  基金
市場:  英國
發行者:  AXA Equitable
國際證券識別碼(ISIN):  GB00B784NS11 
資產類別:  股票
  • 晨星評級:
  • 總資產: 343.19M
AXA Framlington Biotech Fund GBP Z Acc 5.135 +0.090 +1.74%

0P0000XMRD綜觀

 
你可在本頁找到深入的AXA Framlington Biotech Fund - R Accumulation公司檔案,包括0P0000XMRD的主要管理層、總資產、投資策略及聯絡資料,以及各類其他資訊。
類別

Sector Equity Biotechnology

總資產

343.19M

費用

0.83%

基金成立

2012年4月16日

聯絡資訊

地址 100, Esplanade du Général de Gaulle
Paris, 92932
France
電話 +33 1 44 45 70 00
傳真 Paris

主要管理層

名稱 主旨 成立於 直至
Cinney Zhang - 2023 now
Linden Thomson - 2012 now
Peter Hughes Portfolio Manager 2001 2023
自傳 Peter joined Redwheel in July 2023 as a Partner and Portfolio Manager. He will manage the Redwheel Life Changing Treatments strategy. His ambition for the role is to focus on improving patients’ lives, regardless of where they live by investing in companies facilitating improved health care outcomes while providing long-term capital appreciation for investors. Before Redwheel, Peter was Portfolio Manager of the AXA World Funds Longevity Economy fund and AXA Framlington Health fund, specialising in healthcare. Before this, he held appointments at Architas, in roles covering investment research and relationship management. Peter holds a PhD in biochemistry from University College London. He has a master's degree in chemistry from the University of Surrey and is a CFA Charterholder. He is also an ambassador for the Royal Marsden Cancer Charity. Peter was named as a 2021 Rising Star of Asset Management by Financial News.
Dani Saurymper - 2015 2020
自傳 Dani Saurymper joined AXA IM in April 2015 as Fund Manager for the AXA Framlington Health Fund. He joined from Barclays Capital where he was a senior equity research analyst covering European healthcare.
Gemma Game - 2011 2015
Deane Donnigan clinical Specialist 2010 2011
自傳 Deane joined Polar Capital in June 2013 as a senior analyst for the Healthcare team and has over 34 years’ industry experience, including over 15 years within healthcare asset management. She trained as a clinical pharmacist, graduating with a post baccalaureate Doctor of Pharmacy from the University of Georgia. Deane began her career at the Medical College of Georgia, before becoming a clinical specialist in Drug Information and Adult Internal Medicine with Emory University Hospital in Atlanta, Georgia. After several years, she moved to the UK to join Framlington (now AXA Framlington) applying her extensive pharmaceutical expertise working as an analyst for the healthcare unit trust, led by Anthony Milford. She went on to become lead portfolio manager of the Framlington Healthcare and Framlington Biotechnology funds. Deane is both a US and UK citizen.
Andy Smith Portfolio manager 2009 2010
自傳 Andy joined AXA Framlington in April 2008 as Portfolio Manager within the healthcare team with specific responsibility for the AXA Framlington Biotech Fund. Previously, he spent three years at SV Life Sciences where he was responsible for managing a global biotechnology investment fund. From 2004 to 2005 he worked at Schroders as Director and Fund Manager, Global Equities. Between 2002 and 2004 he worked within the Asset Management division of the 3i Group as Investment Manager and then Director.
Deane Donnigan clinical Specialist 2007 2009
自傳 Deane joined Polar Capital in June 2013 as a senior analyst for the Healthcare team and has over 34 years’ industry experience, including over 15 years within healthcare asset management. She trained as a clinical pharmacist, graduating with a post baccalaureate Doctor of Pharmacy from the University of Georgia. Deane began her career at the Medical College of Georgia, before becoming a clinical specialist in Drug Information and Adult Internal Medicine with Emory University Hospital in Atlanta, Georgia. After several years, she moved to the UK to join Framlington (now AXA Framlington) applying her extensive pharmaceutical expertise working as an analyst for the healthcare unit trust, led by Anthony Milford. She went on to become lead portfolio manager of the Framlington Healthcare and Framlington Biotechnology funds. Deane is both a US and UK citizen.
Gareth Powell Portfolio Manager 2004 2007
自傳 Gareth Powell joined Polar Capital in 2007 to establish the healthcare investment team. He is joint manager of the Healthcare Opportunities Fund. He joined Framlington in 1999, later becoming a portfolio manager on the Framlington Health Fund. In 2002, Gareth helped launch the Framlington Biotech Fund, which he managed until his departure. Gareth studied biochemistry at Oxford, during which time he worked at Yamanouchi, a leading Japanese pharmaceutical company (later to become Astellas), as well as various academic laboratories including the Sir William Dunn School of Pathology, the Wolfson Institute for Biomedical Research and Oxford Business School. He is a CFA charterholder.
Antony Milford - 2001 2007
評論守則
我们鼓励您使用评论,与用户沟通,共享您的观点并向作者及互相提问。 但是,为了获得有价值和期待的高水平评论,请注意以下标准:
  • 丰富对话
  • 保持关注及正确方向。 只发布与所讨论话题相关的材料。
  • 保持尊重。 即使是负面的意见,也可以用积极的外交辞令进行组织。
  • 用标准书写风格。 包括标点和大小写。
  • 注: 评论中如有垃圾和/或促销信息和链接都将被删除。
  • 避免亵渎、诽谤或人身攻击,对于作者或其他用户。
  • 仅允许中文评论。

垃圾邮件或滥发信息的肇事者都将被从网站删除并禁止以后进行注册,这由Investing.com自由决定。

0P0000XMRD評論

寫下您對AXA Framlington Biotech Fund - R Accumulation的看法
 
確定要刪除這個圖表?
 
留言
也張貼至:
 
用新的圖表更換附上的圖表?
1000
由於收到負面的用戶報告,你的評論功能已被暫停。你的狀態會由版主審核。
請等待一分鐘后再次發表評論。
感謝您的評論。請註意,所有的評論都需要我們版主的批準。因此,可能過一些時間您的評論才會出現在我們的網站上。
 
確定要刪除這個圖表?
 
留言
 
用新的圖表更換附上的圖表?
1000
由於收到負面的用戶報告,你的評論功能已被暫停。你的狀態會由版主審核。
請等待一分鐘后再次發表評論。
在留言中加插圖表
確認封鎖

你確定要封鎖 %USER_NAME%?

此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。

%USER_NAME% 已成功加入你的封鎖清單

你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。

舉報此評論

我覺得這個評論是:

評論被加標記

謝謝!

您的報告已被發送到我們的版主審核
以 Google 登入
以電子郵件註冊